BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1135 related articles for article (PubMed ID: 25262236)

  • 1. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome.
    Das M; Son WY; Buckett W; Tulandi T; Holzer H
    Reprod Biomed Online; 2014 Nov; 29(5):545-51. PubMed ID: 25262236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on clinical effect on infertility women with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer].
    Yu R; Lin J; Zhao JZ; Wang PY; Xiao SQ; Zhang W
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):250-4. PubMed ID: 22781109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the efficiency between in-vitro maturation and in-vitro fertilization after early follicular phase GnRH agonist down-regulation in infertile women with polycystic ovary syndrome].
    Zhu RR; Xiao SQ; Zhao JZ; Lin J; Wang PY; Jin CC; Jin WM
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):833-7. PubMed ID: 24444560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial.
    Zheng X; Guo W; Zeng L; Zheng D; Yang S; Xu Y; Wang L; Wang R; Mol BW; Li R; Qiao J
    Hum Reprod; 2022 Jan; 37(2):242-253. PubMed ID: 34849920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
    Xiao ZN; Peng JL; Yang J; Xu WM
    Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count.
    Ho VNA; Braam SC; Pham TD; Mol BW; Vuong LN
    Hum Reprod; 2019 Jun; 34(6):1055-1064. PubMed ID: 31111879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical application of in vitro maturation of human immature oocytes for infertile women with polycystic ovary syndrome].
    Xu YP; Xiang HF; Zou WW; Li ZL; Zhang ZG; Zhou P; Cao YX
    Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):14-8. PubMed ID: 22455687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type.
    Lambalk CB; Banga FR; Huirne JA; Toftager M; Pinborg A; Homburg R; van der Veen F; van Wely M
    Hum Reprod Update; 2017 Sep; 23(5):560-579. PubMed ID: 28903472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparision of in vitro maturation applied in PCOS and non-PCOS patients undergo stimulated and unstimulated protocols].
    Wang P; Zhao J; Jin C; Yu R; Lin J; Zhu R; Wu Y
    Zhonghua Fu Chan Ke Za Zhi; 2014 Dec; 49(12):903-8. PubMed ID: 25608990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes.
    Walls ML; Hunter T; Ryan JP; Keelan JA; Nathan E; Hart RJ
    Hum Reprod; 2015 Jan; 30(1):88-96. PubMed ID: 25355587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial.
    Jacob SL; Brewer C; Tang T; Picton HM; Barth JH; Balen AH
    Hum Reprod; 2016 Dec; 31(12):2756-2764. PubMed ID: 27816925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT).
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Alexopoulou E; Kolibianakis EM
    Hum Reprod; 2010 Mar; 25(3):683-9. PubMed ID: 20008886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of GnRH antagonist in the treatment of patients with polycystic ovary syndrome undergoing IVF: a systematic review and meta analysis.
    Xiao J; Chen S; Zhang C; Chang S
    Gynecol Endocrinol; 2013 Mar; 29(3):187-91. PubMed ID: 23194095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.